Patents Examined by Bruck Kifle
  • Kinase inhibitors exhibiting anti-cancer activity and their method of use
    Patent number: 11697654
    Abstract: Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 11, 2023
    Assignee: ALLCRON PHARMA INC.
    Inventors: Ayyappan Rajasekaran, Jon Swanson, Peter Kane, Julia Foster
  • Macrocyclic indoles as Mcl-1 inhibitors
    Patent number: 11691989
    Abstract: Disclosed is compound of formula I and the pharmaceutically acceptable salts and solvates thereof, wherein R, R1a, R1b, R1h, L2, L3, #, #, # are as defined as set forth in the re) specification. Disclosed is compound of formula I for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: July 4, 2023
    Assignees: ASCENTAGE PHARMA (SUZHOU) CO., LTD., THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ASCENTAGE PHARMA GROUP CORP LIMITED
    Inventors: Hao Chen, Wenming Chen, Chao Li, Dongbo Li, Yu Jing, Guozhi Tang, Yunlong Zhou, Shaomeng Wang, Chao-Yie Yang
  • ATM kinase inhibitors and compositions and methods of use thereof
    Patent number: 11685734
    Abstract: Provided are certain ATM kinase inhibitors of Formula I: Also provided herein are compositions of such compounds, and methods of their use.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: June 27, 2023
    Assignee: CHDI Foundation, Inc.
    Inventors: Leticia M. Toledo-Sherman, Celia Dominguez, Perla Breccia, Amanda J. Van De Poël, Grant Wishart, Huw D. Vater, William R. K. Esmieu, Cole Clissold, Wesley P. Blackaby
  • Inhibition of Olig2 activity
    Patent number: 11685722
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 27, 2023
    Assignee: CURTANA PHARMACEUTICALS, INC.
    Inventors: Graham Beaton, Stanton F. McHardy, Ambrosio Lopez, Jr., Bismarck Campos, Hua-Yu Leo Wang
  • MYST family histone acetyltransferase inhibitors
    Patent number: 11685732
    Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: June 27, 2023
    Assignee: Epizyme, Inc.
    Inventors: Darren Martin Harvey, John Emmerson Campbell, Kenneth William Duncan
  • NLRX1 ligands
    Patent number: 11680045
    Abstract: Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including inflammatory, immune-mediated, and/or chronic inflammatory gastrointestinal diseases; systemic immune-mediated diseases; cancers; and infectious diseases.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: June 20, 2023
    Assignee: LANDOS BIOPHARMA, INC.
    Inventors: Josep Bassaganya-Riera, Andrew Leber, Raquel Hontecillas
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11673901
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: June 13, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • Imidazopyrimidine compounds and uses thereof
    Patent number: 11673891
    Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: June 13, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., Children's Medical Center Corporation
    Inventors: Ofer Levy, David J. Dowling, Francesco Borriello, David A. Scott, Spencer E. Brightman, Frederic Feru
  • MCL1 inhibitors
    Patent number: 11667652
    Abstract: The present disclosure generally relates to compounds of Formula (I) and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: June 6, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, David W. Lin, Jonathan William Medley, Devan Naduthambi, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang, QingMing Zhu
  • Tricyclic compounds as histone methyltransferase inhibitors
    Patent number: 11661410
    Abstract: The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: May 30, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Ming Yu, Qing Xu, Manuel Zancanella
  • MK2 inhibitors, synthesis thereof, and intermediates thereto
    Patent number: 11655257
    Abstract: The present invention provides methods of preparing a MK2 inhibitor, and intermediates related thereto.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: May 23, 2023
    Assignee: Celgene CAR LLC
    Inventors: Gregg Brian Feigelson, Maryll E. Geherty, Richard Martin Heid, Jr., Mohit Kothare, Hon-Wah Man, Alexander L. Ruchelman, John F. Traverse, Kelvin Hin-Yeong Yong, Chengmin Zhang
  • Tetrahydrobenzofurodiazepinone compound and pharmaceutical use thereof
    Patent number: 11643417
    Abstract: The present invention provides a compound having a Pim-1 inhibitory activity. The present invention provides a compound of Formula [I] or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the same, and a pharmaceutical use thereof, and the like. wherein each symbol is as defined in the description.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: May 9, 2023
    Assignee: Japan Tobacco Inc.
    Inventors: Masafumi Inoue, Yosuke Ogoshi, Takayuki Furukawa, Takuya Machida, Ikuo Mitani, Kazuhito Harada, Yuichi Nakagawa, Nobutaka Yamaoka
  • Melanocortin 4 receptor antagonists and uses thereof
    Patent number: 11643412
    Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, X1, Y1, Y2, Y3, Y4 and Y5 are defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: May 9, 2023
    Assignee: Pfizer Inc.
    Inventors: Christopher Ryan Butler, Michelle Renee Garnsey, Kevin Alexander Ogilvie, Jana Polivkova, Matthew Forrest Sammons, Aaron Christopher Smith, Qingyi Yang
  • MCL-1 inhibitors
    Patent number: 11643400
    Abstract: The present disclosure generally relates to compounds and pharmaceutical compositions that may be used in methods of treating cancer.
    Type: Grant
    Filed: February 9, 2021
    Date of Patent: May 9, 2023
    Assignee: Gilead Sciences, Inc.
    Inventors: Hang Chu, Juan A. Guerrero, Anna E. Hurtley, Tae H. Hwang, Lan Jiang, Darryl Kato, Tetsuya Kobayashi, John E. Knox, Scott E. Lazerwith, Xiaofen Li, David W. Lin, Jonathan W. Medley, Michael L. Mitchell, Devan Naduthambi, Zachary Newby, Neil H. Squires, Vickie H. Tsui, Chandrasekar Venkataramani, William J. Watkins, Hong Yang
  • IRE1 small molecule inhibitors
    Patent number: 11634403
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: April 25, 2023
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Elizabeth Bettigole
  • Tubulin binding compounds and therapeutic use thereof
    Patent number: 11633393
    Abstract: Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: April 25, 2023
    Assignee: BeyondSpring Pharmaceuticals, Inc.
    Inventors: Lan Huang, Santosh Ambadas Khedkar, Michel O. Steinmetz
  • Polycyclic compounds as allosteric SHP2 inhibitors
    Patent number: 11634435
    Abstract: The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: April 25, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Elena S. Koltun, Naing N. Aay, Andreas Buckl, Kevin T. Mellem, Brian R. Blank, Jennifer Pitzen, Gang Wang, Ashutosh S. Jogalekar, Walter S. Won, Christos Tzitzilonis, Jie Jack Li, Adrian Liam Gill, James Joseph Cregg
  • Lymphoid-specific tyrosine phosphatase (LYP) inhibitors
    Patent number: 11629130
    Abstract: The present disclosure relates to novel lymphoid-specific tyrosine phosphatase (LYP, encoded by the PTPN22 gene) inhibitors, and to methods of making and using the novel LYP inhibitors. Thus, the compounds according to the disclosure may be used for treating diseases or disorders associated with PTPN22 genetic polymorphism, including type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosis, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, Hashimoto thyroiditis, and other rarer diseases. Furthermore, these LYP inhibitors may be served for a novel class of cancer immunotherapy. The compounds can be injected or orally administered.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: April 18, 2023
    Assignee: Purdue Research Foundation
    Inventors: Zhong-Yin Zhang, Jianping Lin
  • Compound with anticancer activity
    Patent number: 11629152
    Abstract: A compound having anticancer activity, or a pharmaceutically acceptable salt thereof is provided. Used is a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: (wherein, L1 and L2 are the same or different and each represents a group represented by one formula selected from the group consisting of formulas (A) to (F), and S represents a group represented by one formula selected from the group consisting of formulas (S1) to (S18)).
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: April 18, 2023
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Kenji Uchida, Ryohei Kawai, Keisuke Yamamoto, Toshimi Kanai, Hideo Ikota, Takashi Imaeda, Kei Yoshida
  • Forms and compositions of a MK2 inhibitor
    Patent number: 11629153
    Abstract: The present invention provides solid forms of an MK2 inhibitor, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: April 18, 2023
    Assignee: Celgene CAR LLC
    Inventors: Jianxin Han, Lianfeng Huang, Uday Jain, Ying Li, John Malona, Kevin Molter, Chittari Pabba, Alexander L. Ruchelman, Jean Xu, Daozhong Zou